CSIMarket
 


Humacyte Inc   (HUMA)
Other Ticker:  
 

Humacyte Inc 's Working Capital Ratio

HUMA's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 6.79 below Humacyte Inc average.

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Working Capital Ratio than Humacyte Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 437 to 530.

Explain Working Capital Ratio
How much in Current Assets HUMA´s has?
What is the value of HUMA´s Current Liabilities?


HUMA Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change -15.46 % 2.98 % 119.28 % 77.19 % -15.72 %
Y / Y Current Assets Change -41.1 % -37.54 % -36.04 % -32.76 % -28.49 %
Working Capital Ratio MRQ 6.79 10.59 5.67 7.88 9.75
HUMA's Total Ranking # 530 # 437 # 851 # 673 # 599
Seq. Current Liabilities Change 32.92 % -51.75 % 20.54 % 9.35 % 61.93 %
Seq. Current Assets Change -14.69 % -9.93 % -13.2 % -11.69 % -9.54 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 58
Healthcare Sector # 262
Overall Market # 530


Working Capital Ratio Statistics
High Average Low
20.75 11.19 2.11
(Dec 31 2021)   (Jun 30 2021)




Financial Statements
Humacyte Inc 's Current Liabilities $ 15 Millions Visit HUMA's Balance sheet
Humacyte Inc 's Current Assets $ 103 Millions Visit HUMA's Balance sheet
Source of HUMA's Sales Visit HUMA's Sales by Geography


Cumulative Humacyte Inc 's Working Capital Ratio

HUMA's Working Capital Ratio for the trailling 12 Months

HUMA Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -15.46 % 2.98 % 119.28 % 77.19 % -15.72 %
Y / Y Current Assets TTM Growth -41.1 % -37.54 % -36.04 % -32.76 % -28.49 %
Working Capital Ratio TTM 7.34 8.05 9.09 12.33 15.88
Total Ranking TTM # 3211 # 3570 # 3433 # 4035 # 3743
Seq. Current Liabilities TTM Growth 32.92 % -51.75 % 20.54 % 9.35 % 61.93 %
Seq. Current Assets TTM Growth -14.69 % -9.93 % -13.2 % -11.69 % -9.54 %


On the trailing twelve months basis In spite of the year on year decrease in HUMA's Current Liabilities to $15.14 millions, cumulative Working Capital Ratio to 7.34 below the HUMA average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 151 other companies have achieved higher Working Capital Ratio than Humacyte Inc . While Working Capital Ratio overall ranking has improved so far to 3211, from total ranking during the twelve months ending second quarter 2023 at 3570.

Explain Working Capital Ratio
How much in Current Assets HUMA´s has?
What is the value of HUMA´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 152
Healthcare Sector # 885
Within the Market # 3211


trailing twelve months Working Capital Ratio Statistics
High Average Low
16.18 12.6 7.34
(Jun 30 2022)   (Sep 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Tourmaline Bio Inc   18.64 $ 151.047  Millions$ 8.105  Millions
Avrobio Inc   18.47 $ 109.170  Millions$ 5.912  Millions
Compass Therapeutics Inc   18.26 $ 166.584  Millions$ 9.124  Millions
4d Molecular Therapeutics Inc   18.07 $ 328.243  Millions$ 18.163  Millions
Icosavax Inc   18.06 $ 235.307  Millions$ 13.030  Millions
Neumora Therapeutics Inc   18.05 $ 525.735  Millions$ 29.123  Millions
Fusion Pharmaceuticals Inc   17.97 $ 203.265  Millions$ 11.312  Millions
Hillevax Inc   17.58 $ 333.195  Millions$ 18.958  Millions
Relay Therapeutics Inc   16.39 $ 831.798  Millions$ 50.748  Millions
Denali Therapeutics Inc   16.06 $ 1,142.884  Millions$ 71.180  Millions
Crispr Therapeutics Ag  15.83 $ 1,760.586  Millions$ 111.234  Millions
Cabaletta Bio Inc   15.65 $ 166.178  Millions$ 10.616  Millions
Voyager Therapeutics Inc   15.03 $ 261.925  Millions$ 17.427  Millions
Iteos Therapeutics Inc   14.28 $ 619.128  Millions$ 43.349  Millions
Caribou Biosciences Inc   14.27 $ 350.693  Millions$ 24.572  Millions
Aura Biosciences Inc   14.13 $ 153.888  Millions$ 10.894  Millions
Vor Biopharma Inc   14.12 $ 164.438  Millions$ 11.645  Millions
Pharmacyte Biotech Inc   14.08 $ 73.748  Millions$ 5.240  Millions
Vigil Neuroscience Inc   13.79 $ 139.847  Millions$ 10.142  Millions
Molecular Partners Ag  13.35 $ 192.459  Millions$ 14.416  Millions
Anavex Life Sciences Corp   13.29 $ 154.386  Millions$ 11.617  Millions
Elevation Oncology inc   12.99 $ 98.797  Millions$ 7.607  Millions
Ambrx Biopharma Inc   12.80 $ 233.818  Millions$ 18.268  Millions
Replimune Group Inc   12.76 $ 508.175  Millions$ 39.832  Millions
Allogene Therapeutics inc   12.58 $ 473.454  Millions$ 37.636  Millions
Scholar Rock Holding Corp  11.70 $ 228.465  Millions$ 19.530  Millions
Kymera Therapeutics Inc   11.66 $ 375.694  Millions$ 32.219  Millions
Protara Therapeutics Inc   11.49 $ 77.813  Millions$ 6.775  Millions
Tarsus Pharmaceuticals Inc   11.15 $ 259.277  Millions$ 23.249  Millions
Inhibrx Inc   10.76 $ 363.297  Millions$ 33.760  Millions

Date modified: 2023-11-12T03:13:24+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com